18 may, 2018, 09:28 | author: denise dawson.activity.

40 under 40 - bbj class of 2018.

german chancellor angela merkel (bottom left) was straightforward when she said enlargment was not on the table at the sofia summit ..

eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..

while all of the drugs work on cgrp, they don�t all work the same way. three of them target the cgrp molecule itself. aimovig goes after cgrp's receptor in the brain..